News

Lupin Limited announced that its Operations and Finance Committee has allotted 30967 fully paid-up equity shares of Rs 2 each, increasing the company`s issued and paid-up share capital to Rs 91,45,31,722 consisting of 45,72,65,861 equity shares of Rs 2 each, following the exercise of vested options under the company`s stock option plans for employees and its subsidiaries.

Lupin announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet. The U.S. FDA has approved Lupin`s Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet as bioequivalent to the reference listed drug (RLD) Lokelma� for Oral Suspension of AstraZeneca Pharmaceuticals LP and is indicated for the treatment of hyperkalemia in adults. Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma�) had estimated annual sales of USD 568 million in the U.S. (IQVIA MAT Jun 2026).

Net profit of Lupin rose 16.08% to Rs 1415.00 crore in the quarter ended June 2026 as against Rs 1219.03 crore during the previous quarter ended June 2025. Sales rose 33.32% to Rs 8217.23 crore in the quarter ended June 2026 as against Rs 6163.75 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales8217.236163.75 33 OPM %29.8128.02 - PBDT2470.211714.52 44 PBT2017.361415.54 43 NP1415.001219.03 16 Powered by Capital Market - Live News

Lupin announced that it has received approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes. The U.S. FDA has approved Lupin`s Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes as bioequivalent to the reference listed drug (RLD) Valium� Injection 10 mg/2 mL (5 mg/mL) of Hoffman-LaRoche, Inc. and is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes had estimated annual sales of USD 77.9 million in the U.S. (IQVIA MAT May 2026).

Lupin announced that following approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial in the United States. Lupin`s Sugammadex Injection is the bioequivalent to Bridion� Injection of Merck, Sharp & Dohme LLC (Merck) and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.